Xcess Biosciences Inc.
7144 N Harlem Ave #169
Chicago, IL 60631 USA

http://www.xcessbio.com
Toll free: 1-866-706-2330
Fax: 1-619- 810-0718
Email: info@xcessbio.com

Ubiquitin C-terminal Hydrolase-L3 (UCH-L3) Inhibitor – TCID

Chemical Name: 4,5,6,7-Tetrachloro-1H-Indene-1,3(2H)-dione



Molecular Weight:	283.92
Formula:	$C_9H_2Cl_4O_2$
Purity:	≥98%
CAS#:	30675-13-9
Solubility:	DMSO up to 50 mM
Storage	Powder: 4 °C 1 year DMSO: 4 °C 3 months -20 °C 1 year

Biological Activity:

TCID is a novel potent and selective inhibitor of ubiquitin C-terminal hydrolase-L3 (UCH-L3) with an IC_{50} ~0.6 μM. It has ~125-fold greater selectivity over UCH-L1 (ubiquitin C-terminal hydrolase L1, IC_{50} ~75 μM). TCID can diminish glycine transporter GlyT2 ubiquitination in brain stem and spinal cord primary neurons.

How to Use:

In vitro: TCID was used at 10-30 μM final concentration in various in vitro assays.

In vivo: n/a

Reference:

1. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. (2003) Chem Biol. 10(9):837-46.
2. de Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. (2013) PLoS One. 8(3):e58863.